BACKGROUND: Both schizophrenia and epilepsy have been linked to increased risk of sudden cardiac death (SCD). We hypothesized that DNA variants within genes previously associated with schizophrenia and epilepsy may contribute to an increased risk of SCD. OBJECTIVE: To investigate the contribution to SCD susceptibility of DNA variants previously implicated in schizophrenia and epilepsy. METHODS: From the ongoing Oregon Sudden Unexpected Death Study, comparisons were performed among 340 SCD cases presenting with ventricular fibrillation and 342 controls. We tested for the association between 17 single-nucleotide polymorphisms (SNPs) mapped to 14 loci previously implicated in schizophrenia and epilepsy by using logistic regression and assuming additive, dominant, and recessive genetic models. RESULTS: The minor allele of the nonsynonymous SNP rs10503929 within the neuregulin 1 gene was associated with SCD under all 3 investigated models, with the strongest association for the recessive genetic model (recessive P = 4.01 × 10(-5), odds ratio [OR] 4.04; additive P = 2.84 × 10(-7), OR 1.9; and dominant P = 9.01 × 10(-6), OR 2.06). To validate our findings, we further explored the association of this variant in the Harvard Cohort SCD study. The SNP rs10503929 was associated with an increased risk of SCD under the recessive genetic model (P = .0005, OR 2.7). This missense variation causes a methionine to threonine change and functional effects are currently unknown. CONCLUSIONS: The observed association between a schizophrenia-related neuregulin 1 gene variant and SCD may represent the first evidence of coexisting genetic susceptibility between 2 conditions that have an established clinical overlap. Further investigation is warranted to explore the molecular mechanisms of this variant in the pathogenesis of SCD.
BACKGROUND: Both schizophrenia and epilepsy have been linked to increased risk of sudden cardiac death (SCD). We hypothesized that DNA variants within genes previously associated with schizophrenia and epilepsy may contribute to an increased risk of SCD. OBJECTIVE: To investigate the contribution to SCD susceptibility of DNA variants previously implicated in schizophrenia and epilepsy. METHODS: From the ongoing Oregon Sudden Unexpected Death Study, comparisons were performed among 340 SCD cases presenting with ventricular fibrillation and 342 controls. We tested for the association between 17 single-nucleotide polymorphisms (SNPs) mapped to 14 loci previously implicated in schizophrenia and epilepsy by using logistic regression and assuming additive, dominant, and recessive genetic models. RESULTS: The minor allele of the nonsynonymous SNP rs10503929 within the neuregulin 1 gene was associated with SCD under all 3 investigated models, with the strongest association for the recessive genetic model (recessive P = 4.01 × 10(-5), odds ratio [OR] 4.04; additive P = 2.84 × 10(-7), OR 1.9; and dominant P = 9.01 × 10(-6), OR 2.06). To validate our findings, we further explored the association of this variant in the Harvard Cohort SCD study. The SNP rs10503929 was associated with an increased risk of SCD under the recessive genetic model (P = .0005, OR 2.7). This missense variation causes a methionine to threonine change and functional effects are currently unknown. CONCLUSIONS: The observed association between a schizophrenia-related neuregulin 1 gene variant and SCD may represent the first evidence of coexisting genetic susceptibility between 2 conditions that have an established clinical overlap. Further investigation is warranted to explore the molecular mechanisms of this variant in the pathogenesis of SCD.
Authors: Yechiel Friedlander; David S Siscovick; Patrick Arbogast; Bruce M Psaty; Sheila Weinmann; Rozenn N Lemaitre; T E Raghunathan; Leonard A Cobb Journal: Atherosclerosis Date: 2002-05 Impact factor: 5.162
Authors: D Ruschena; P E Mullen; P Burgess; S M Cordner; J Barry-Walsh; O H Drummer; S Palmer; C Browne; C Wallace Journal: Br J Psychiatry Date: 1998-04 Impact factor: 9.319
Authors: Hreinn Stefansson; Engilbert Sigurdsson; Valgerdur Steinthorsdottir; Soley Bjornsdottir; Thordur Sigmundsson; Shyamali Ghosh; Jon Brynjolfsson; Steinunn Gunnarsdottir; Omar Ivarsson; Thomas T Chou; Omar Hjaltason; Birgitta Birgisdottir; Helgi Jonsson; Vala G Gudnadottir; Elsa Gudmundsdottir; Asgeir Bjornsson; Brynjolfur Ingvarsson; Andres Ingason; Sigmundur Sigfusson; Hronn Hardardottir; Richard P Harvey; Donna Lai; Mingdong Zhou; Daniela Brunner; Vincent Mutel; Acuna Gonzalo; Greg Lemke; Jesus Sainz; Gardar Johannesson; Thorkell Andresson; Daniel Gudbjartsson; Andrei Manolescu; Michael L Frigge; Mark E Gurney; Augustine Kong; Jeffrey R Gulcher; Hannes Petursson; Kari Stefansson Journal: Am J Hum Genet Date: 2002-07-23 Impact factor: 11.025
Authors: Christine M Albert; Claudia U Chae; Francine Grodstein; Lynda M Rose; Kathryn M Rexrode; Jeremy N Ruskin; Meir J Stampfer; JoAnn E Manson Journal: Circulation Date: 2003-04-14 Impact factor: 29.690
Authors: Lavinia Athanasiu; Morten Mattingsdal; Anna K Kähler; Andrew Brown; Omar Gustafsson; Ingrid Agartz; Ina Giegling; Pierandrea Muglia; Sven Cichon; Marcella Rietschel; Olli P H Pietiläinen; Leena Peltonen; Elvira Bramon; David Collier; David St Clair; Engilbert Sigurdsson; Hannes Petursson; Dan Rujescu; Ingrid Melle; Vidar M Steen; Srdjan Djurovic; Ole A Andreassen Journal: J Psychiatr Res Date: 2010-02-24 Impact factor: 4.791
Authors: Adriana Huertas-Vazquez; Christopher P Nelson; Janet S Sinsheimer; Kyndaron Reinier; Audrey Uy-Evanado; Carmen Teodorescu; Jo Ayala; Alistair S Hall; Karen Gunson; Jonathan Jui; Nilesh J Samani; Sumeet S Chugh Journal: Int J Cardiol Heart Vasc Date: 2015-06-01